Northern Trust
BIOA

Northern Trust’s BioAge Labs BIOA Stock Holding History

Northern Trust’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.41M Buy
343,166
+119,037
+53% +$2.15M ﹤0.01% 2305
2026
Q1 		$3.92M Buy
224,129
+56,677
+34% +$1.09M ﹤0.01% 2593
2025
Q4 		$2.22M Sell
167,452
-19,116
-10% -$169K ﹤0.01% 2936
2025
Q3 		$1.1M Buy
186,568
+33,559
+22% +$157K ﹤0.01% 3362
2025
Q2 		$632K Buy
153,009
+63,441
+71% +$256K ﹤0.01% 3579
2025
Q1 		$337K Buy
89,568
+2,325
+3% +$10.8K ﹤0.01% 3744
2024
Q4 		$505K Buy
+87,243
New +$1.5M ﹤0.01% 3652

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Northern Trust's BIOA Position: Q2 2026 in Review

Northern Trust increased its BioAge Labs (BIOA) stake by 53% in Q2 2026, buying an estimated $2.15M and bringing the position to 343,166 shares worth $8.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Northern Trust first reported a position in BIOA in Q4 2024 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Northern Trust held 343,166 shares of BioAge Labs worth $8.41M as of Q2 2026.
  • Northern Trust bought 119,037 BioAge Labs shares in Q2 2026, an estimated $2.15M.
  • BioAge Labs made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2305 holding.
  • Northern Trust first reported a position in BioAge Labs in Q4 2024 and has held it in 7 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.